Sentence examples for bypassing agent from inspiring English sources

The bypassing agent recombinant factor VIIa (rFVIIa) is efficacious in treating bleeding in hemophilia patients with inhibitors.

Therapeutic intervention in the coagulation cascade often involves modulating the levels of inactive factors (e.g., FVIII or FIX replacement therapy for hemophilia A and B patients) or active factors (e.g., addition of FVIIa, procoagulation agent such as bypassing agent for hemophilia patients with inhibitors) 30– 32 or inhibitors of anticoagulants (e.g., anti-TFPI 33).

This is approved for use as a bypassing agent in hemophiliac patients who have inhibitor antibodies to factor VIII or IX, but its use in a broader range of applications in life-threatening hemorrhage has been extensively reported [ 40].

Capitalising on the popularity of e-readers such as the Kindle, a new generation of writers is bypassing agents and publishers and using the flexible pricing model of ebooks to offer their work directly to the public at rock-bottom prices.

In those cases, doctors prescribe "bypassing agents" ― yet another specialty drug that can help the blood clot, but needs even more intensive monitoring. .

In those cases, doctors prescribe "bypassing agents" ― yet another specialty drug that can help the blood clot, but needs even more intensive monitoring.

Nash is, after all, only the latest in a string of nobodies who've become sponsorable online somebodies by bypassing agents and taking their talents directly to the web.

If it's more important to get published, move on to Plan B. Shopping to Publishers I encourage writers with niche or non-commercial projects to shop directly to publishers, bypassing agents (though some want or need to go the agent route first).

Instead, bypassing agents have to be used.

20, 21 Two bypassing agents are currently available: the activated prothrombin complex concentrate (APCC) FEIBA® (Baxter AG, Vienna, Austria) and recombinant-activated FVII (rFVIIa; NovoSeven®, Novo Nordisk, Bagsværd, Denmark).

Our findings reveal that a small proportion of patients with hemophilia (n = 5; 4.9 %) developed inhibitors to clotting factor products and required treatment with bypassing agents.